BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at began coverage on shares of BIOLASE (NASDAQ:BIOLFree Report) in a report released on Friday. The brokerage issued a sell rating on the medical technology company’s stock.

Other equities analysts also recently issued reports about the company. Benchmark reiterated a speculative buy rating and set a $0.40 target price on shares of BIOLASE in a research report on Tuesday, May 14th. Maxim Group cut BIOLASE from a strong-buy rating to a hold rating in a research report on Friday, May 24th.

Check Out Our Latest Stock Analysis on BIOL

BIOLASE Trading Down 35.1 %

BIOLASE stock opened at $0.05 on Friday. BIOLASE has a 52-week low of $0.04 and a 52-week high of $10.31. The company has a market cap of $1.55 million, a P/E ratio of 0.00 and a beta of 0.74. The company has a quick ratio of 0.64, a current ratio of 1.17 and a debt-to-equity ratio of 34.06. The business has a 50-day simple moving average of $0.15 and a two-hundred day simple moving average of $0.43.

BIOLASE (NASDAQ:BIOLGet Free Report) last announced its earnings results on Monday, May 13th. The medical technology company reported ($0.36) earnings per share (EPS) for the quarter. BIOLASE had a negative net margin of 43.56% and a negative return on equity of 1,782.73%. The business had revenue of $10.13 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC boosted its holdings in BIOLASE, Inc. (NASDAQ:BIOLFree Report) by 1,068.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.79% of the company’s stock.

BIOLASE Company Profile

(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

See Also

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with's FREE daily email newsletter.